2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE


Ascelia Pharma AB (publ) (ticker: ACE) today published its year-end report for the period July 2019 – December 2019, which is now available on the company’s website (the financial year will going forward follow the calendar year):


  • Julie Waras Brogren appointed as Chief Commercial Officer
  • Detailed preparations ahead of the start of the Phase III study SPARKLE with Mangoral
  • Four sites opened for patient enrollment in December and one additional site opened in January 2020 for the SPARKLE study


  • Operating result of SEK -22.9M (SEK -7.2M)
  • Earnings per share of SEK -1.16 (SEK -0.49)
  • Cash flow from operations of SEK -16.8M (SEK -9.1M)
  • Cash and marketable securities of SEK 184.2M (SEK 42.1M)


  • Operating result of SEK -36.9M (SEK -11.2M)
  • Earnings per share of SEK -1.70 (SEK -0.75)
  • Cash flow from operations of SEK -36.9M (SEK -13.0M)
  • Cash and marketable securities of SEK 184.2M (SEK 42.1M)

“During December 2019 and January 2020, we opened five sites in the US and Europe for enrollment of patients to our pivotal Phase III study SPARKLE. This is a decisive step as we accelerate the development of our lead compound Mangoral towards expected sales launch in 2022“, said Magnus Corfitzen, CEO at Ascelia Pharma.

A presentation for analysts, media and investors will be held on 14 February at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos, CMO Carl Bjartmar and CCO Julie Waras Brogren. The presentation will be held in English. The presentation can be followed live via the link:

It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website:

To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 850 558 366
UK: +44 333 300 9265
US: +1
833 526 8397

For more information, please contact:
Magnus Corfitzen, CEO
Tel. 46 735 179 110

Mikael Widell, IR & Communications Manager
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on 14 February 2020.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral and Oncoral – currently in clinical development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit


Analysguiden/Carlsquare updates its view on Ascelia Pharma and raises target share price

Today Analysguiden/Carlsquare published an updated equity research report on Ascelia Pharma.  As part of their updated view, they raise their target share price to 41.90 kr from 34.80 kr.

Issue and repurchase of series C shares for share saving program

Pursuant to the authorization granted by the annual general meeting on 14 November 2019, the board of directors of Ascelia Pharma AB (”Ascelia”) has resolved to issue and immediately thereafter repurchase  510,545 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2019, which was adopted by the annual general meeting on 14 November 2019.

Vator Securities: Ascelia Pharma: A rocket roll out is the key to success

February 20, 2020